New SPECT/CT technique shows impressive biomarker identification, offers increased access for prostate cancer patients

A novel SPECT/CT acquisition method can accurately detect radiopharmaceutical biodistribution in a convenient manner for prostate cancer patients, opening the door for more personalized treatment. Utilizing lead-212 (212Pb), the new imaging technique has the potential to change practice and increase access for patients around the world. The first-in-human images from this method are published in the Journal of Nuclear Medicine.